Abstract
The pharmacokinetics of moxalactam were determined in eight patients with end stage renal disease who were undergoing chronic hemodialysis. The mean half-life of moxalactam in the interdialysis period was 19 h, with a range of 9 to 30 h. The mean half-life of moxalactam during dialysis was 4 +/- 0.58 h. Serum levels of 30 +/- 10 micrograms/ml were present 24 h after a 1-g dose in the interdialysis period. A dose of 1 g at the end of each dialysis period in patients undergoing thrice-weekly hemodialysis would provide levels far in excess of the minimal inhibitory levels against Enterobacteriaceae.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bolton W. K., Scheld W. M., Spyker D. A., Overby T. L., Sande M. A. Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction. Antimicrob Agents Chemother. 1980 Dec;18(6):933–938. doi: 10.1128/aac.18.6.933. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Brogard J. M., Comte F., Pinget M. Pharmacokinetics of cephalosporin antibiotics. Antibiot Chemother (1971) 1978;25:123–162. doi: 10.1159/000401060. [DOI] [PubMed] [Google Scholar]
- Chodos J., Francke E. L., Saltzman M., Neu H. C. Pharmacokinetics of intravenous cefotaxime in patients undergoing chronic hemodialysis. Ther Drug Monit. 1981;3(1):71–74. [PubMed] [Google Scholar]
- Fillastre J. P., Leroy A., Godin M., Oksenhendler G., Humbert G. Pharmacokinetics of cefoxitin sodium in normal subjects and in uraemic patients. J Antimicrob Chemother. 1978 Jul;4(B):79–83. doi: 10.1093/jac/4.suppl_b.79. [DOI] [PubMed] [Google Scholar]
- Fu K. P., Aswapokee P., Ho I., Matthijssen C., Neu H. C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother. 1979 Nov;16(5):592–597. doi: 10.1128/aac.16.5.592. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lam M., Manion C. V., Czerwinski A. W. Pharmacokinetics of moxalactam in patients with renal insufficiency. Antimicrob Agents Chemother. 1981 Mar;19(3):461–464. doi: 10.1128/aac.19.3.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Neu H. C., Aswapokee N., Fu K. P., Aswapokee P. Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds. Antimicrob Agents Chemother. 1979 Aug;16(2):141–149. doi: 10.1128/aac.16.2.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Parsons J. N., Romano J. M., Levison M. E. Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers. Antimicrob Agents Chemother. 1980 Feb;17(2):226–228. doi: 10.1128/aac.17.2.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Srinivasan S., Fu K. P., Neu H. C. Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers. Antimicrob Agents Chemother. 1981 Feb;19(2):302–305. doi: 10.1128/aac.19.2.302. [DOI] [PMC free article] [PubMed] [Google Scholar]